DE602006006797D1 - Zusammensetzungen mit kontrollierter freisetzung für interferon auf basis von pegt/pbt-blockcopolymeren - Google Patents

Zusammensetzungen mit kontrollierter freisetzung für interferon auf basis von pegt/pbt-blockcopolymeren

Info

Publication number
DE602006006797D1
DE602006006797D1 DE602006006797T DE602006006797T DE602006006797D1 DE 602006006797 D1 DE602006006797 D1 DE 602006006797D1 DE 602006006797 T DE602006006797 T DE 602006006797T DE 602006006797 T DE602006006797 T DE 602006006797T DE 602006006797 D1 DE602006006797 D1 DE 602006006797D1
Authority
DE
Germany
Prior art keywords
composition
pegt
compositions
controlled
block copolymers
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602006006797T
Other languages
English (en)
Inventor
Anne Chantal Bechet
Dijkhuizen-Radersma Riemke Van
Martin Stigter
Jeroen Mattijs Bezemer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
OCTOPLUS POLYACTIVE SCIENCES B
Biolex Therapeutics Inc
Original Assignee
OCTOPLUS POLYACTIVE SCIENCES B
Biolex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by OCTOPLUS POLYACTIVE SCIENCES B, Biolex Inc filed Critical OCTOPLUS POLYACTIVE SCIENCES B
Publication of DE602006006797D1 publication Critical patent/DE602006006797D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
DE602006006797T 2005-01-07 2006-01-06 Zusammensetzungen mit kontrollierter freisetzung für interferon auf basis von pegt/pbt-blockcopolymeren Active DE602006006797D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05075043A EP1679065A1 (de) 2005-01-07 2005-01-07 Zubereitung mit kontrollierter Freisetzung von Interferon auf PEGT/PBT-Block-Copolymer-Basis
PCT/NL2006/000006 WO2006085747A1 (en) 2005-01-07 2006-01-06 Controlled release compositions for interferon based on pegt/pbt block copolymers

Publications (1)

Publication Number Publication Date
DE602006006797D1 true DE602006006797D1 (de) 2009-06-25

Family

ID=34937981

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602006006797T Active DE602006006797D1 (de) 2005-01-07 2006-01-06 Zusammensetzungen mit kontrollierter freisetzung für interferon auf basis von pegt/pbt-blockcopolymeren

Country Status (24)

Country Link
US (3) US7736674B2 (de)
EP (4) EP1679065A1 (de)
JP (2) JP2008526837A (de)
KR (2) KR101354521B1 (de)
CN (2) CN101791396A (de)
AT (1) ATE431134T1 (de)
AU (2) AU2006213168B2 (de)
BR (1) BRPI0606514A2 (de)
CA (1) CA2594434A1 (de)
CY (1) CY1109297T1 (de)
DE (1) DE602006006797D1 (de)
DK (1) DK1843749T3 (de)
ES (1) ES2327267T3 (de)
HK (1) HK1152644A1 (de)
HR (1) HRP20090434T1 (de)
IL (2) IL184431A (de)
MX (1) MX2007008293A (de)
PL (1) PL1843749T3 (de)
PT (1) PT1843749E (de)
RS (1) RS51129B (de)
RU (2) RU2409348C2 (de)
SG (1) SG158856A1 (de)
SI (1) SI1843749T1 (de)
WO (1) WO2006085747A1 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1679065A1 (de) 2005-01-07 2006-07-12 OctoPlus Sciences B.V. Zubereitung mit kontrollierter Freisetzung von Interferon auf PEGT/PBT-Block-Copolymer-Basis
EP2175865A4 (de) * 2007-07-25 2012-01-11 Biolex Therapeutics Inc Interferon-arzneiprodukte mit kontrollierter freisetzung und behandlung von hcv-infektionen damit
EP2055299A1 (de) 2007-10-23 2009-05-06 Koninklijke Philips Electronics N.V. Verfahren zur Herstellung von Polymermikropartikeln
CN102215821B (zh) 2007-10-23 2013-05-08 皇家飞利浦电子股份有限公司 用于制备聚合物微颗粒的方法
BRPI0910198A2 (pt) * 2008-06-30 2016-01-12 Silenseed Ltd composição para administração a partir de um sítio local de um agente baseado em nucleotídeos e método para tratar um sujeito sofrendo de uma doença requerendo tratamento local com um agente baseado em nucleotídeo.
MX2011008963A (es) 2009-03-05 2012-02-01 Ascendis Pharma As Profarmacos portadores de interferon alfa.
MX366228B (es) * 2011-03-25 2019-07-03 Selecta Biosciences Inc Nanoportadores sinteticos de liberacion mediada por osmosis.
CN104436197A (zh) 2011-10-21 2015-03-25 艾伯维公司 至少两种直接作用抗病毒剂的组合产品
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
JP5677645B2 (ja) 2011-10-21 2015-02-25 アッヴィ・インコーポレイテッド 少なくとも２種の直接作用型抗ウイルス剤、およびリバビリンを含むがインターフェロンを含まない、ｈｃｖを治療するための方法
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
WO2016046817A1 (en) 2014-09-24 2016-03-31 Vital Beverages Global Inc. Compositions and methods for selective gi tract delivery
EP3448392A4 (de) 2016-04-28 2020-01-15 Emory University Alkynhaltige therapeutische nukleotid- und nukleosidzusammensetzungen und verwendungen im zusammenhang damit
WO2021009040A1 (en) 2019-07-12 2021-01-21 Basf Se Process for producing microparticles laden with a volatile organic active

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL137652C (de) * 1962-07-11
US5372808A (en) * 1990-10-17 1994-12-13 Amgen Inc. Methods and compositions for the treatment of diseases with consensus interferon while reducing side effect
US5192743A (en) * 1992-01-16 1993-03-09 Genentech, Inc. Reconstitutable lyophilized protein formulation
ES2187506T3 (es) 1992-04-24 2003-06-16 Chienna Bv Dispositivos para la prevencion de adhesiones de tejidos.
US5711968A (en) 1994-07-25 1998-01-27 Alkermes Controlled Therapeutics, Inc. Composition and method for the controlled release of metal cation-stabilized interferon
EP0582459B1 (de) * 1992-08-07 1998-01-07 Takeda Chemical Industries, Ltd. Herstellung von Mikrokapseln, die wasserlösliche Arzneimittel enthalten
US5643605A (en) 1993-10-25 1997-07-01 Genentech, Inc. Methods and compositions for microencapsulation of adjuvants
US6117455A (en) 1994-09-30 2000-09-12 Takeda Chemical Industries, Ltd. Sustained-release microcapsule of amorphous water-soluble pharmaceutical active agent
US5612052A (en) 1995-04-13 1997-03-18 Poly-Med, Inc. Hydrogel-forming, self-solvating absorbable polyester copolymers, and methods for use thereof
DE19545257A1 (de) 1995-11-24 1997-06-19 Schering Ag Verfahren zur Herstellung von morphologisch einheitlichen Mikrokapseln sowie nach diesem Verfahren hergestellte Mikrokapseln
CA2238829A1 (en) 1995-11-30 1997-06-05 Board Of Regents, The University Of Texas System Methods and compositions for the diagnosis and treatment of cancer
US5792477A (en) 1996-05-07 1998-08-11 Alkermes Controlled Therapeutics, Inc. Ii Preparation of extended shelf-life biodegradable, biocompatible microparticles containing a biologically active agent
US5980948A (en) * 1996-08-16 1999-11-09 Osteotech, Inc. Polyetherester copolymers as drug delivery matrices
US6277888B1 (en) 1997-02-27 2001-08-21 Welfide Corporation Drug composition
PT975334E (pt) * 1997-04-17 2004-03-31 Amgen Inc Microparticulas biodegradaveis para a libertacao sustentada de farmacos terapeuticos
AR012448A1 (es) 1997-04-18 2000-10-18 Ipsen Pharma Biotech Composicion en forma de microcapsulas o de implantes que comprende un excipiente biodegradable, polimero o co-polimero, o una mezcla de talesexcipientes, y una sustancia activa o una mezcla de sustancias activas, procedimiento para la preparacion de una sustancia soluble en agua de elevada
US6531154B1 (en) 1997-06-10 2003-03-11 Brown University Research Foundation Modulated release from biocompatible polymers
IL134901A0 (en) * 1997-10-24 2001-05-20 Lilly Co Eli Insoluble insulin compositions
US6270802B1 (en) 1998-10-28 2001-08-07 Oakwood Laboratories L.L.C. Method and apparatus for formulating microspheres and microcapsules
US6194006B1 (en) 1998-12-30 2001-02-27 Alkermes Controlled Therapeutics Inc. Ii Preparation of microparticles having a selected release profile
AU2002400A (en) * 1999-01-12 2000-08-01 Kyowa Hakko Kogyo Co. Ltd. Telomerase inhibitors
US6204308B1 (en) 1999-03-01 2001-03-20 Novartis Ag Organic compounds
US20030206928A1 (en) * 1999-04-07 2003-11-06 Pertti Tormala Bioactive, bioabsorbable surgical polyethylene glycol and polybutylene terephtalate copolymer composites and devices
US6291013B1 (en) 1999-05-03 2001-09-18 Southern Biosystems, Inc. Emulsion-based processes for making microparticles
PL352499A1 (en) 1999-07-15 2003-08-25 Takeda Chemical Industries Ltd Compositions of prolonged active substance release, method of obtaining them and their applications
EP1090928B1 (de) 1999-09-30 2004-05-26 Chienna B.V. Mit bioaktiven Mitteln beladene Polymeren
US6465425B1 (en) * 2000-02-10 2002-10-15 Alkermes Controlled Therapeutics, Inc. Microencapsulation and sustained release of biologically active acid-stable or free sulfhydryl-containing proteins
US6495164B1 (en) 2000-05-25 2002-12-17 Alkermes Controlled Therapeutics, Inc. I Preparation of injectable suspensions having improved injectability
US6479065B2 (en) 2000-08-10 2002-11-12 Alkermes Controlled Therapeutics, Inc. Process for the preparation of polymer-based sustained release compositions
US6471995B1 (en) 2000-09-27 2002-10-29 Alkermes Controlled Therapeutics, Inc. Ii Apparatus and method for preparing microparticles using liquid-liquid extraction
JP4557409B2 (ja) * 2000-11-13 2010-10-06 日東電工株式会社 多孔質ポリイミドの製造方法及び多孔質ポリイミド
ES2250502T3 (es) 2000-12-13 2006-04-16 Merckle Gmbh Microparticulas con un perfil de liberacion mejorado y procedimient0 para su preparacion.
EP1356809A4 (de) 2000-12-28 2008-05-14 Takeda Pharmaceutical Retardzubereitungen
RU2191012C1 (ru) 2001-06-20 2002-10-20 Научно-исследовательский испытательный центр (медико-биологической защиты) Государственного научно-исследовательского испытательного института военной медицины МО РФ Глазные капли для лечения эндотелиально-эпителиальной дистрофии роговицы
JP2005508220A (ja) 2001-10-24 2005-03-31 パーリ・ゲーエムベーハー 薬用組成物調製用具
AU2002343681B2 (en) * 2001-11-12 2006-07-06 Alkermes Controlled Therapeutics, Inc. Biocompatible polymer blends and uses thereof
TWI252111B (en) * 2001-12-14 2006-04-01 Solvay Pharm Gmbh Matrix film tablet with controlled release of a natural mixture of conjugated estrogens
EP1466596B8 (de) 2001-12-26 2017-01-11 Takeda Pharmaceutical Company Limited Mikrosphäre und verfahren zu deren herstellung
PT1532985T (pt) 2002-06-25 2017-01-20 Takeda Pharmaceuticals Co Processo de produção de uma composição de libertação sustentada
ES2625343T3 (es) 2003-07-15 2017-07-19 Evonik Corporation Método para la preparación de formulaciones de liberación controlada
EA200601904A1 (ru) 2004-04-15 2007-02-27 Алкермес, Инк. Система отсроченного высвобождения лекарственного средства на основе полимеров
EP1679065A1 (de) 2005-01-07 2006-07-12 OctoPlus Sciences B.V. Zubereitung mit kontrollierter Freisetzung von Interferon auf PEGT/PBT-Block-Copolymer-Basis

Also Published As

Publication number Publication date
CN101791396A (zh) 2010-08-04
EP2266535B1 (de) 2013-03-06
US7867518B2 (en) 2011-01-11
JP4887542B2 (ja) 2012-02-29
IL208175A0 (en) 2010-12-30
AU2006213168A1 (en) 2006-08-17
US7736674B2 (en) 2010-06-15
RU2010138739A (ru) 2012-03-27
CY1109297T1 (el) 2014-07-02
HRP20090434T1 (hr) 2009-09-30
US20100074868A1 (en) 2010-03-25
EP1886668B1 (de) 2012-11-14
IL184431A (en) 2012-03-29
US8163307B2 (en) 2012-04-24
EP2266535A3 (de) 2011-06-15
IL184431A0 (en) 2007-10-31
WO2006085747A1 (en) 2006-08-17
BRPI0606514A2 (pt) 2010-01-19
EP1679065A1 (de) 2006-07-12
CN101137349B (zh) 2013-01-02
RU2007130090A (ru) 2009-02-20
KR20100109983A (ko) 2010-10-11
EP1843749A1 (de) 2007-10-17
CA2594434A1 (en) 2006-08-17
ES2327267T3 (es) 2009-10-27
HK1152644A1 (en) 2012-03-09
ATE431134T1 (de) 2009-05-15
EP1886668A1 (de) 2008-02-13
EP1843749B1 (de) 2009-05-13
US20090226532A1 (en) 2009-09-10
JP2011016836A (ja) 2011-01-27
PL1843749T3 (pl) 2009-10-30
MX2007008293A (es) 2007-12-07
SG158856A1 (en) 2010-02-26
CN101137349A (zh) 2008-03-05
EP2266535A2 (de) 2010-12-29
JP2008526837A (ja) 2008-07-24
RS51129B (sr) 2010-10-31
AU2006213168B2 (en) 2011-09-15
KR101354521B1 (ko) 2014-01-22
US20080008733A1 (en) 2008-01-10
SI1843749T1 (sl) 2009-10-31
RU2409348C2 (ru) 2011-01-20
PT1843749E (pt) 2009-08-17
KR20070118225A (ko) 2007-12-14
AU2010224413B2 (en) 2012-03-22
DK1843749T3 (da) 2009-09-07
AU2010224413A1 (en) 2010-10-14

Similar Documents

Publication Publication Date Title
DE602006006797D1 (de) Zusammensetzungen mit kontrollierter freisetzung für interferon auf basis von pegt/pbt-blockcopolymeren
ES2535084T3 (es) Proteínas N-glicosiladas recombinantes procedentes de células procariotas
WO2007127440A3 (en) Heterofunctional poly(ethylene glycol) containing acid-labile amino protecting groups and uses thereof
EP1721625A3 (de) Bioabbaubare medizinische Vorrichtungen mit verbesserter mechanischer Festigkeit und pharmakologischer Funktion
DE602005023315D1 (de) Antimikrobielle peptide mit einem arginin- und /oder lysin-haltigen motiv
ATE505551T1 (de) Konjugate zur zuführung an knochen und verfahren zu deren verwendung beim hinführen von proteinen zum knochen
HRP20070268A2 (en) Site-directed modification of fviii
EA200700435A1 (ru) Рентгеноконтрастные полимерные стенты
ATE531374T1 (de) Vorrichtung auf polymerbasis mit verzögerter freisetzung
ATE544802T1 (de) Polyglutamat-aminosäure-konjugate und verfahren
DE502005001377D1 (de) Thermoplastische formmassen auf basis von styrolcopolymeren und polyamiden
TW200634181A (en) Electroplating composition and method
ATE422880T1 (de) Heterofunktionelle copolymere von glycerol und polyethylenglykol, ihre konjugate und zusammensetzungen
BRPI0516568A (pt) biomateriais consistindo em ácido hialurÈnico sulfatado e gelana, bem como composição farmacêutica e uso dos mesmos
WO2007053512A3 (en) Novel protein transduction domains and uses therefor
ATE345775T1 (de) Zusammensetzungen zur verabreichung von arzneimittelkombinationen
SE0301431D0 (sv) Novel antimicrobial peptides
DE602004021501D1 (de) Gegenüber ionisierender strahlung stabile polyarylestercarbonatzusammensetzungen
TW200722104A (en) Low-toxicity, long-circulating human interferon-α analogs
TW200716178A (en) Macromolecular conjugates of bone morphogenetic protein-7
DE60306144D1 (de) Antistatische Elastomerzuammensetzungen
BRPI0508895A (pt) formas polimorficas e amorfa de {2-flúor-5-[3-((e)-2-piridn-2-il-vinil)-1h-indazol-6-ilamin]- fenil}-amida de ácido 2,5-dimetil-2h-pirazol-3-carboxìlico
BRPI0409424B8 (pt) composição farmacêutica para administração parenteral, e, usos de uma partícula coloidal e de partículas coloidais e uma proteína ou um polipeptídeo
ATE406412T1 (de) Verwendung von isocyanurate und magnesium(hydr)oxide enthaltenden zusammensetzungen zur stabilisierung von halogenhaltigen organischen kunststoffen
RU2005138252A (ru) Композиции на основе акульего жира

Legal Events

Date Code Title Description
8364 No opposition during term of opposition